Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition

Documenti analoghi

• Tertiary lymphoid structure‐related RNA indicator as metastasis risk factor in nasopharyngeal carcinoma
  di: Zhaozheng Hou, et al.
  Pubblicazione: (2025)
• Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma
  di: Lan Peng, et al.
  Pubblicazione: (2026)
• The efficacy and safety of EGFR‐TKI in recurrent/metastatic nasopharyngeal carcinoma patients: A systematic review and meta‐analysis
  di: Zeqi An, et al.
  Pubblicazione: (2024)
• Derivative Gains/Losses: Quantity Risk, Corporate Hedge Effectiveness and Earnings
  di: Chee Kwong Lau
  Pubblicazione: (2026)
• The cold ocean-warm land pattern: Model simulation and relevance to climate change detection
  di: Anthony J. Broccoli, Ngar Cheung Lau and Mary Jo Nath
  Pubblicazione: (1998)